Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies

Allen, 1992, The cardiotoxicity of chemotherapeutic drugs, Semin Oncol, 19, 529

Jain, 2000, Cardiotoxicity of doxorubicin and other anthracycline derivatives, J Nucl Cardiol, 7, 53, 10.1067/mnc.2000.103324

Lipshultz, 1995, Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer, N Engl J Med, 332, 1738, 10.1056/NEJM199506293322602

Lanzarini, 2000, Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines, Am Heart J, 140, 315, 10.1067/mhj.2000.108237

Sorensen, 1995, Cardiac function in Wilms' tumor survivors, J Clin Oncol, 13, 1546, 10.1200/JCO.1995.13.7.1546

Silber, 1993, Increased risk of cardiac dysfunction after anthracyclines in girls, Med Pediatr Oncol, 21, 477, 10.1002/mpo.2950210704

Biancaniello, 1980, Doxorubicin cardiotoxicity in children, J Pediatr, 97, 45, 10.1016/S0022-3476(80)80128-4

Hershman, 2008, Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma, J Clin Oncol, 26, 3159, 10.1200/JCO.2007.14.1242

Godoy, 1997, Anthracycline-induced cardiotoxicity in children with malignancies, Acta Paediatr Jpn, 39, 188, 10.1111/j.1442-200X.1997.tb03579.x

Pein, 2004, Cardiac abnormalities 15years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy, Br J Cancer, 91, 37, 10.1038/sj.bjc.6601904

Saltiel, 1983, Doxorubicin (adriamycin) cardiomyopathy, West J Med, 139, 332

Singal, 1998, Doxorubicin-induced cardiomyopathy, N Engl J Med, 339, 900, 10.1056/NEJM199809243391307

Kremer, 2002, Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review, Ann Oncol, 13, 503, 10.1093/annonc/mdf118

Xu, 2001, Effects by doxorubicin on the myocardium are mediated by oxygen free radicals, Life Sci, 68, 889, 10.1016/S0024-3205(00)00990-5

Simunek, 2009, Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol Rep, 61, 154, 10.1016/S1734-1140(09)70018-0

Horenstein, 2000, Molecular basis of anthracycline-induced cardiotoxicity and its prevention, Mol Genet Metab, 71, 436, 10.1006/mgme.2000.3043

Doroshow, 1980, Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin, J Clin Invest, 65, 128, 10.1172/JCI109642

Goormaghtigh, 1980, Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity, Biochem Pharmacol, 29, 3003, 10.1016/0006-2952(80)90050-7

Schlame, 2000, The biosynthesis and functional role of cardiolipin, Prog Lipid Res, 39, 257, 10.1016/S0163-7827(00)00005-9

Kashfi, 1990, Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues, Biochem Pharmacol, 40, 1441, 10.1016/0006-2952(90)90438-Q

Ventura-Clapier, 2004, Energy metabolism in heart failure, J Physiol, 555, 1, 10.1113/jphysiol.2003.055095

Cole, 2006, The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity, Cardiovasc Res, 69, 186, 10.1016/j.cardiores.2005.07.012

Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol Rev, 56, 185, 10.1124/pr.56.2.6

Papadopoulou, 1999, Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression, Biochem Pharmacol, 57, 481, 10.1016/S0006-2952(98)00305-0

Carvalho, 2010, Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy, Toxicology, 270, 92, 10.1016/j.tox.2010.01.019

Suliman, 2007, The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy, J Clin Invest, 117, 3730

Piantadosi, 2008, Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1, Circ Res, 103, 1232, 10.1161/01.RES.0000338597.71702.ad

Pani, 2000, Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells, Cancer Res, 60, 4654

Kim, 2006, Protective effect of calceolarioside on adriamycin-induced cardiomyocyte toxicity, Eur J Pharmacol, 541, 24, 10.1016/j.ejphar.2006.04.045

Xiong, 2006, Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase, Free Radic Biol Med, 41, 46, 10.1016/j.freeradbiomed.2006.02.024

Vasquez-Vivar, 1997, Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin, Biochemistry, 36, 11293, 10.1021/bi971475e

Kalivendi, 2001, Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium, J Biol Chem, 276, 47266, 10.1074/jbc.M106829200

Moens, 2009, Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor, J Mol Cell Cardiol, 47, 576, 10.1016/j.yjmcc.2009.06.005

Neilan, 2007, Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin, Circulation, 116, 506, 10.1161/CIRCULATIONAHA.106.652339

Duquaine, 2003, Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase, Vasc Med, 8, 101, 10.1191/1358863x03vm476oa

Mukhopadhyay, 2009, Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro, Am J Physiol Heart Circ Physiol, 296, H1466, 10.1152/ajpheart.00795.2008

Fu, 2004, Human neuronal nitric oxide synthase can catalyze one-electron reduction of adriamycin: role of flavin domain, Arch Biochem Biophys, 427, 180, 10.1016/j.abb.2004.04.030

Liu, 2006, Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats, J Biochem Mol Biol, 39, 759, 10.5483/BMBRep.2006.39.6.759

Deng, 2007, Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH, Free Radic Biol Med, 42, 466, 10.1016/j.freeradbiomed.2006.11.013

Gilleron, 2009, NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis, Biochem Biophys Res Commun, 388, 727, 10.1016/j.bbrc.2009.08.085

Wojnowski, 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity, Circulation, 112, 3754, 10.1161/CIRCULATIONAHA.105.576850

Blanco, 2008, Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer, Cancer, 112, 2789, 10.1002/cncr.23534

May, 1980, Solution chemistry studies of adriamycin–iron complexes present in vivo, Eur J Cancer, 16, 1275, 10.1016/0014-2964(80)90189-9

Kappus, 1980, In vivo studies on adriamycin-induced lipid peroxidation and effects of ferrous ions, Dev Toxicol Environ Sci, 8, 635

Xu, 2005, Molecular pharmacology of the interaction of anthracyclines with iron, Mol Pharmacol, 68, 261, 10.1124/mol.105.013383

Minotti, 1998, The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium, FASEB J, 12, 541, 10.1096/fasebj.12.7.541

Miranda, 2003, Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin, Blood, 102, 2574, 10.1182/blood-2003-03-0869

Panjrath, 2007, Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model, J Am Coll Cardiol, 49, 2457, 10.1016/j.jacc.2007.02.060

Barton, 2000, Transfusion iron overload in adults with acute leukemia: manifestations and therapy, Am J Med Sci, 319, 73, 10.1097/00000441-200002000-00001

Dhalla, 2000, Role of oxidative stress in cardiovascular diseases, J Hypertens, 18, 655, 10.1097/00004872-200018060-00002

Bjelogrlic, 2005, Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice, Basic Clin Pharmacol Toxicol, 97, 311, 10.1111/j.1742-7843.2005.pto_166.x

Nitobe, 2003, Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes, Cardiovasc Res, 57, 119, 10.1016/S0008-6363(02)00646-6

Liu, 2007, Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 762

Vedam, 2010, Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice, Am J Physiol Heart Circ Physiol, 298, H1832, 10.1152/ajpheart.01047.2009

Shan, 2003, Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells, J Mol Cell Cardiol, 35, 1135, 10.1016/S0022-2828(03)00229-3

Fan, 2008, Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity, Circ Res, 103, 1270, 10.1161/CIRCRESAHA.108.182832

Kim, 2009, Extracellular heat shock protein 60, cardiac myocytes, and apoptosis, Circ Res, 105, 1186, 10.1161/CIRCRESAHA.109.209643

Rayner, 2008, Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A, Circ Res, 103, 133, 10.1161/CIRCRESAHA.108.172155

Nozaki, 2004, Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice, Circulation, 110, 2869, 10.1161/01.CIR.0000146889.46519.27

Riad, 2008, Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice, Eur J Heart Fail, 10, 233, 10.1016/j.ejheart.2008.01.004

Chen, 2007, Effects of oxymatrine on expression of nuclear factor kappa B in kidneys of rats with adriamycin-induced chronic renal fibrosis, Nan Fang Yi Ke Da Xue Xue Bao, 27, 345

Wang, 2002, Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide, Biochem J, 367, 729, 10.1042/bj20020752

Ueno, 2006, Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo, J Pharmacol Sci, 101, 151, 10.1254/jphs.FP0050980

Youn, 2005, Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment, Mol Cell Biochem, 270, 13, 10.1007/s11010-005-2541-2

Bruynzeel, 2007, Caspase-dependent and -independent suppression of apoptosis by monoHER in doxorubicin treated cells, Br J Cancer, 96, 450, 10.1038/sj.bjc.6603598

Maejima, 2005, Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation, J Mol Cell Cardiol, 38, 163, 10.1016/j.yjmcc.2004.10.012

d'Anglemont de Tassigny, 2008, The volume-sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2, Eur J Heart Fail, 10, 39, 10.1016/j.ejheart.2007.11.002

Kalivendi, 2005, Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium, Biochem J, 389, 527, 10.1042/BJ20050285

Arai, 2000, Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription, Circ Res, 86, 8, 10.1161/01.RES.86.1.8

Holmberg, 1990, Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum, Circ Res, 67, 272, 10.1161/01.RES.67.2.272

Saeki, 2002, Doxorubicin directly binds to the cardiac-type ryanodine receptor, Life Sci, 70, 2377, 10.1016/S0024-3205(02)01524-2

Caroni, 1981, The cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca2+ exchange of dog heart sarcolemmal vesicles, FEBS Lett, 130, 184, 10.1016/0014-5793(81)81115-5

Keung, 1991, L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations, J Clin Invest, 87, 2108, 10.1172/JCI115241

Favero, 1995, Hydrogen peroxide stimulates the Ca2+ release channel from skeletal muscle sarcoplasmic reticulum, J Biol Chem, 270, 25557, 10.1074/jbc.270.43.25557

Nakagawa, 2000, Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta, Nature, 403, 98, 10.1038/47513

Jang, 2004, Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats, FEBS Lett, 577, 483, 10.1016/j.febslet.2004.10.053

Sawyer, 2002, Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity, Circulation, 105, 1551, 10.1161/01.CIR.0000013839.41224.1C

Lim, 2004, Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes, J Biol Chem, 279, 8290, 10.1074/jbc.M308033200

Solem, 1996, Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin, J Mol Cell Cardiol, 28, 1023, 10.1006/jmcc.1996.0095

Chacon, 1992, A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes, Biochem J, 281, 871, 10.1042/bj2810871

Gabrielson, 2007, Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury, Cancer Res, 67, 1436, 10.1158/0008-5472.CAN-06-3721

Peng, 2005, Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes, J Biol Chem, 280, 13148, 10.1074/jbc.M410838200

Negro, 2006, erbB2 is required for G protein-coupled receptor signaling in the heart, Proc Natl Acad Sci, 103, 15889, 10.1073/pnas.0607499103

Tripathy, 2004, Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer, Clin Breast Cancer, 5, 293, 10.3816/CBC.2004.n.033

Tokarska-Schlattner, 2005, Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply, Am J Physiol Heart Circ Physiol, 289, H37, 10.1152/ajpheart.01057.2004

Keller, 1986, Nuclear magnetic resonance study of high-energy phosphate stores in models of adriamycin cardiotoxicity, Magn Reson Med, 3, 834, 10.1002/mrm.1910030603

Nicolay, 1987, Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity, Biochim Biophys Acta, 929, 5, 10.1016/0167-4889(87)90234-5

Bordoni, 1999, The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes, Biochim Biophys Acta, 1440, 100, 10.1016/S1388-1981(99)00113-4

Chatham, 1990, The relationship between cardiac function and metabolism in acute adriamycin-treated perfused rat hearts studied by 31P and 13C NMR spectroscopy, J Mol Cell Cardiol, 22, 1187, 10.1016/0022-2828(90)90082-D

Thomas, 1994, Free radical inactivation of rabbit muscle creatinine kinase: catalysis by physiological and hydrolyzed ICRF-187 (ICRF-198) iron chelates, Free Radic Res, 21, 387, 10.3109/10715769409056591

Mihm, 2002, Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase, Br J Pharmacol, 135, 581, 10.1038/sj.bjp.0704495

Suzuki, 2001, A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes, Am J Physiol Regul Integr Comp Physiol, 280, R1399, 10.1152/ajpregu.2001.280.5.R1399

Picard, 1998, Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure, J Cardiovasc Pharmacol, 31, S294, 10.1097/00005344-199800001-00082

Pieske, 1999, Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium, Circulation, 99, 1802, 10.1161/01.CIR.99.14.1802

Sayed-Ahmed, 2001, Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy, Pharmacol Toxicol, 89, 140, 10.1034/j.1600-0773.2001.d01-148.x

Luscher, 2000, Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs, Circulation, 102, 2434, 10.1161/01.CIR.102.19.2434

Miller, 1993, Endothelin-mediated cardiorenal hemodynamic and neuroendocrine effects are attenuated by nitroglycerin in vivo, Am J Hypertens, 6, 156, 10.1093/ajh/6.2.156

Bien, 2007, The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy, Cancer Res, 67, 10428, 10.1158/0008-5472.CAN-07-1344

Yang, 2004, Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice, Circulation, 109, 255, 10.1161/01.CIR.0000105701.98663.D4

Spinale, 2007, Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function, Physiol Rev, 87, 1285, 10.1152/physrev.00012.2007

Goetzenich, 2009, Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig, J Heart Lung Transplant, 28, 1087, 10.1016/j.healun.2009.06.025

Spallarossa, 2006, Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase, Cardiovasc Res, 69, 736, 10.1016/j.cardiores.2005.08.009

Tokarska-Schlattner, 2010, Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes, Am J Physiol Regul Integr Comp Physiol, 298, R1075, 10.1152/ajpregu.00360.2009

Singh, 2010, Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats, J Cardiovasc Pharmacol, 55, 139, 10.1097/FJC.0b013e3181c87e17

Dowd, 2001, Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo, J Clin Invest, 108, 585, 10.1172/JCI200111334

Horie, 2010, Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin–ErbB pathway, Cardiovasc Res, 87, 656, 10.1093/cvr/cvq148

Andrieu-Abadie, 1999, l-Carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation, FASEB J, 13, 1501, 10.1096/fasebj.13.12.1501

d'Anglemont de Tassigny, 2004, Volume-sensitive chloride channels (ICl,vol) mediate doxorubicin-induced apoptosis through apoptotic volume decrease in cardiomyocytes, Fundam Clin Pharmacol, 18, 531, 10.1111/j.1472-8206.2004.00273.x

Mukhopadhyay, 2007, Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity, J Am Coll Cardiol, 50, 528, 10.1016/j.jacc.2007.03.057

Mukhopadhyay, 2010, CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes, Cardiovasc Res, 85, 773, 10.1093/cvr/cvp369

Hydock, 2009, Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model, J Cardiovasc Pharmacol Ther, 14, 59, 10.1177/1074248408329449

Torti, 1986, Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy, Cancer Res, 46, 3722

Bristow, 1982, Toxic cardiomyopathy due to doxorubicin, Hosp Pract (Off Ed), 17, 101, 10.1080/21548331.1982.11702439

Takemura, 2007, Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management, Prog Cardiovasc Dis, 49, 330, 10.1016/j.pcad.2006.10.002

Hengel, 2006, Subacute anthracycline cardiotoxicity, Heart Lung Circ, 15, 59, 10.1016/j.hlc.2005.06.003

Saini, 1987, Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases, Ann Intern Med, 106, 814, 10.7326/0003-4819-106-6-814

Cohen, 1982, Reversible doxorubicin-induced congestive heart failure, Arch Intern Med, 142, 1570, 10.1001/archinte.1982.00340210168032

McKillop, 1983, Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity, Am Heart J, 106, 1048, 10.1016/0002-8703(83)90651-8

Tjeerdsma, 1999, Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables, Heart, 81, 419, 10.1136/hrt.81.4.419

Panjrath, 2006, Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging, J Nucl Cardiol, 13, 415, 10.1016/j.nuclcard.2006.03.002

Gabrielson, 2008, Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography, Mol Imaging, 7, 132, 10.2310/7290.2008.00015

Migrino, 2008, Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography, Ultrasound Med Biol, 34, 208, 10.1016/j.ultrasmedbio.2007.07.018

Klewer, 1992, Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer, J Am Coll Cardiol, 19, 394, 10.1016/0735-1097(92)90497-B

Elbl, 2003, The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography, Neoplasma, 50, 191

Marchandise, 1989, Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics, Am Heart J, 118, 92, 10.1016/0002-8703(89)90077-X

Stoddard, 1992, Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans, J Am Coll Cardiol, 20, 62, 10.1016/0735-1097(92)90138-D

Lipshultz, 2004, The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia, N Engl J Med, 351, 145, 10.1056/NEJMoa035153

Hayakawa, 2001, Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer, Med Pediatr Oncol, 37, 4, 10.1002/mpo.1155

Suzuki, 1998, Elevated B-type natriuretic peptide levels after anthracycline administration, Am Heart J, 136, 362, 10.1053/hj.1998.v136.89908

Erttmann, 1988, Pharmacokinetics of doxorubicin in man: dose and schedule dependence, J Cancer Res Clin Oncol, 114, 509, 10.1007/BF00391502

Creech, 1980, An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients, Cancer, 46, 433, 10.1002/1097-0142(19800801)46:3<433::AID-CNCR2820460302>3.0.CO;2-6

Schroeder, 2005, Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat, Drug Metab Dispos, 33, 1367, 10.1124/dmd.105.005546

Hasinoff, 1990, The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane), Drug Metab Dispos, 18, 344

Lebrecht, 2007, Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats, Br J Pharmacol, 151, 771, 10.1038/sj.bjp.0707294

Barry, 2008, Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane, J Clin Oncol, 26, 1106, 10.1200/JCO.2007.12.2481

Tebbi, 2007, Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease, J Clin Oncol, 25, 493, 10.1200/JCO.2005.02.3879

Hensley, 2009, American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants, J Clin Oncol, 27, 127, 10.1200/JCO.2008.17.2627

van Acker, 1993, Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice, Cancer Res, 53, 4603

van Acker, 2001, New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity, Free Radic Biol Med, 31, 31, 10.1016/S0891-5849(01)00546-9

van Acker, 1995, Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity, Br J Pharmacol, 115, 1260, 10.1111/j.1476-5381.1995.tb15034.x

van Acker, 1997, Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin, Clin Cancer Res, 3, 1747

Bruynzeel, 2007, The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study, Br J Cancer, 97, 1084, 10.1038/sj.bjc.6603994

Kalay, 2006, Protective effects of carvedilol against anthracycline-induced cardiomyopathy, J Am Coll Cardiol, 48, 2258, 10.1016/j.jacc.2006.07.052

Georgakopoulos, 2010, Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up, Am J Hematol, 85, 894, 10.1002/ajh.21840

Tallaj, 2005, Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure, J Heart Lung Transplant, 24, 2196, 10.1016/j.healun.2004.12.108

Jensen, 1996, Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy, Lancet, 347, 297, 10.1016/S0140-6736(96)90469-9

Sacco, 2001, Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat, Eur J Pharmacol, 414, 71, 10.1016/S0014-2999(01)00782-8

al-Shabanah, 1998, Captopril ameliorates myocardial and hematological toxicities induced by adriamycin, Biochem Mol Biol Int, 45, 419

Sacco, 2009, ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat, Vascul Pharmacol, 50, 166, 10.1016/j.vph.2009.01.001

Ibrahim, 2009, Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity, Pharmacol Res, 60, 373, 10.1016/j.phrs.2009.05.007

Ramond, 2008, Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts, Exp Biol Med (Maywood), 233, 76, 10.3181/0706-RM-152

Engert, 2010, Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial, J Clin Oncol, 28, 2239, 10.1200/JCO.2009.25.1835

Fisher, 2005, Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity, Circulation, 111, 1601, 10.1161/01.CIR.0000160359.49478.C2

Di, 2010, Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells, Breast Cancer Res Treat, 124, 349, 10.1007/s10549-010-0765-7

Das, 2010, Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction, Proc Natl Acad Sci U S A, 107, 18202, 10.1073/pnas.1006965107

Gross, 2011, Evidence for pleiotropic effects of phosphodiesterase-5 (PDE5) inhibitors: emerging concepts in cancer and cardiovascular medicine, Circ Res, 108, 1040, 10.1161/RES.0b013e31821d2c31

Tatlidede, 2009, Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage, Free Radic Res, 43, 195, 10.1080/10715760802673008

Ajijola, 2008, Usefulness of cardiac resynchronization therapy in the management of doxorubicin-induced cardiomyopathy, Am J Cardiol, 101, 1371, 10.1016/j.amjcard.2007.12.037

Ward, 2004, Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare, J Heart Lung Transplant, 23, 1040, 10.1016/j.healun.2003.08.014

van Dalen, 2010, Different anthracycline derivates for reducing cardiotoxicity in cancer patients, Cochrane Database Syst Rev, CD005006

Suter, 2007, Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial, J Clin Oncol, 25, 3859, 10.1200/JCO.2006.09.1611

Eschenhagen, 2011, Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 13, 1, 10.1093/eurjhf/hfq213